Nanosonics (NAN) H2 2024 earnings summary

Executive summary

• FY24 revenue reached AUD 170 million (up 2% year-over-year), with a strong second half recovery as hospital capital budgets improved.

• Capital unit sales rose 24% in H2, driving a 14% sequential revenue increase; recurring consumables and service revenue grew 9% to AUD 121.8 million.

• Trophon business achieved 50% penetration in North America, with strategies to access remaining market and private physician segment.

• CORIS reached a key milestone with FDA De Novo submission; regulatory process is ongoing with no unexpected delays.

• Free cash flow was AUD 20.4 million, with cash reserves of AUD 129.6 million and no debt, supporting R&D and potential M&A.

Financial highlights

• FY24 revenue was AUD 170 million, up 2% year-over-year, with a significant second half recovery.

• Capital revenue declined 11% to AUD 48.2 million, but second half capital revenue rose 20% over the first half.

• Consumables and service revenue grew 9% to AUD 121.8 million, with 11% growth in the second half.

• Gross margin for the year was 77.9%, down 0.8 points; second half margin was 76.3% due to a one-off manufacturing slowdown.

• Operating expenses rose 10% to AUD 125.6 million, including R&D, ERP, and expansion investments.

Outlook and guidance

• FY25 revenue growth targeted at 8%-12%, driven by capital unit growth, upgrades, and recurring revenue.

• Gross margin expected to recover to 77%-79% in FY25 as manufacturing normalizes.

• Operating expenses projected to grow 6%-10%, slower than FY24, with ongoing R&D and ERP investments.

• Guidance subject to ongoing inflationary pressures on hospital budgets and healthcare costs.